HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.

Abstract
This randomized trial was performed to investigate the efficacy of low-dose rituximab in combination with glucocorticoids for treatment of patients with immune thrombocytopenia (ITP). Sixty-two patients were randomly separated into the glucocorticoids (control) and the experimental (glucocorticoids + rituximab) groups. Patients in both groups received dexamethasone 40 mg/day on days 1-4, followed by decrements of prednisone 60, 30, 15, 10 mg/day on days 5-7, 8-14, 15-21, 22-28, respectively. Patients in the experimental group also received rituximab 100 mg on days 7, 14, 21, 28. The overall response (OR) was similar in both groups at day 28 (experimental group vs. glucocorticoids group: 80.6 vs. 74.2%, P = .938); however, sustained response (SR) was more pronounced in the experimental group as compared to that in the glucocorticoids group (77.4 vs. 38.7%, P < .001). Both groups showed similar incidence of adverse events (experimental group vs. glucocorticoids group: 9.7 vs. 6.5%, P = .325). As expected, B cell depletion was seen in the experimental group. In addition, both groups experienced a significant up-regulation in Treg cell levels, but the up-regulation in the experimental group was maintained at an even higher level and persisted a longer time than those in the glucocorticoids group. Thus, low-dose rituximab combined with short-term glucocorticoids provides an alternative treatment for ITP prior to splenectomy.
AuthorsZhenyu Li, Weiwei Mou, Guang Lu, Jiang Cao, Xupeng He, Xiuying Pan, Kailin Xu
JournalInternational journal of hematology (Int J Hematol) Vol. 93 Issue 1 Pg. 91-8 (Jan 2011) ISSN: 1865-3774 [Electronic] Japan
PMID21188563 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Glucocorticoids
  • Immunologic Factors
  • Rituximab
  • Dexamethasone
  • Prednisone
Topics
  • Adolescent
  • Adult
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage)
  • B-Lymphocytes
  • Dexamethasone (administration & dosage)
  • Drug Therapy, Combination (methods)
  • Female
  • Glucocorticoids (administration & dosage)
  • Humans
  • Immunologic Factors (administration & dosage)
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Prednisone (administration & dosage)
  • Purpura, Thrombocytopenic, Idiopathic (blood, drug therapy)
  • Rituximab
  • T-Lymphocytes, Regulatory

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: